TSE:MDP Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Free MDP Stock Alerts C$1.65 +0.10 (+6.45%) (As of 04/19/2024 ET) Add Compare Share Share Today's RangeC$1.52▼C$1.7050-Day RangeC$1.51▼C$1.8752-Week RangeC$1.12▼C$3.53Volume74,660 shsAverage Volume55,010 shsMarket CapitalizationC$40.36 millionP/E Ratio4.13Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarnings Get Medexus Pharmaceuticals alerts: Email Address Ad AltimetrySecret Bull Market Starts in This Unusual Sector"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. Click for my No. 1 investment, all free of charge, click here. About Medexus Pharmaceuticals Stock (TSE:MDP)Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.Read More MDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDP Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive MDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/07/2024Today4/19/2024Next Earnings (Estimated)6/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:MDP CUSIPN/A CIKN/A Webwww.medexus.com Phone877-633-3987FaxN/AEmployees98Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C$0.40 Trailing P/E Ratio4.13 Forward P/E Ratio15.17 P/E GrowthN/ANet IncomeC$5.88 million Net Margins5.08% Pretax MarginN/A Return on Equity26.14% Return on Assets5.21% Debt Debt-to-Equity Ratio176.88 Current Ratio1.11 Quick RatioN/A Sales & Book Value Annual SalesC$115.72 million Price / Sales0.35 Cash FlowN/A Price / Cash FlowN/A Book ValueC$1.21 per share Price / Book1.36Miscellaneous Outstanding Shares24,460,000Free FloatN/AMarket CapC$40.36 million OptionableNot Optionable Beta1.85 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Kenneth d'EntremontCEO & DirectorMr. Marcel Konrad (Age 48)Chief Financial Officer Comp: $806.64kMr. Ian C. Wildgoose BrownGeneral Counsel & Corporate SecretaryMs. Tina Byers CFAExecutive of Investor RelationsMr. Bill PoncySenior Vice President of Commercial Operations - United StatesMr. Brian PetersVice President of Sales & Marketing - United StatesMore ExecutivesKey CompetitorsViridium Pacific GroupCVE:VIRZomedica Pharmaceuticals Corp. (ZOM.V)CVE:ZOMInMed PharmaceuticalsTSE:INMeta GrowthCVE:METAMediPharm LabsTSE:LABSView All Competitors MDP Stock Analysis - Frequently Asked Questions Should I buy or sell Medexus Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDP shares. View MDP analyst ratings or view top-rated stocks. How have MDP shares performed in 2024? Medexus Pharmaceuticals' stock was trading at C$2.47 at the start of the year. Since then, MDP stock has decreased by 33.2% and is now trading at C$1.65. View the best growth stocks for 2024 here. When is Medexus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 19th 2024. View our MDP earnings forecast. How were Medexus Pharmaceuticals' earnings last quarter? Medexus Pharmaceuticals Inc. (TSE:MDP) posted its quarterly earnings results on Wednesday, February, 7th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.10 by $0.13. The firm earned $34.33 million during the quarter, compared to the consensus estimate of $42.33 million. Medexus Pharmaceuticals had a trailing twelve-month return on equity of 26.14% and a net margin of 5.08%. How do I buy shares of Medexus Pharmaceuticals? Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:MDP) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.